anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a medical image diagnosis apparatus. The medical image diagnosis apparatus is configured to: the operator sequentially performs a plurality of steps, and thereby generates a medical image based on data collected from the subject. The medical image diagnosis device is provided with: a display unit having a display screen; an operation unit that receives an operation of a display screen by an operator; and a control unit that controls the display unit based on the operation received by the operation unit. The display unit is configured to display a plurality of setting screens corresponding to the plurality of steps on the display screen in a superimposed manner. The control unit is configured to switch the uppermost setting screen among the plurality of setting screens based on the operation received by the operation unit. The display unit is further configured to display a plurality of guidance screens for sequentially inputting a plurality of pieces of information in a guidance form in each of the plurality of setting screens.
Disclosed is a process for encapsulating a water-soluble oral care active agent by a shell comprising a hydrophobic polymer. Two routes are described, both of which involve providing a system comprising a hydrophobic polymer, a solvent selected from the group consisting of ethyl formate, ethyl acetate, methyl acetate, propyl acetate, butyl acetate, isobutyl acetate, isopropyl acetate, isoamyl acetate, and mixtures thereof, an oral care active agent, and an oily liquid such as liquid paraffin. In the first route one first has separate phases (viz. the O/O emulsion) from which one allows precipitation by solvent removal. In the other route, the separate phases are created so as to trigger precipitation. In both routes a temperature rise takes place so as to force solvent removal, resulting in solidification.
Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
Both aging and the metabolic syndrome are risk factors for lower urinary tract symptoms (LUTS, including urgency, frequency, nocturia (nighttime urination), and incontinence). This study aims to test whether an oral supplement that targets biological aging pathways can improve lower urinary tract symptoms (LUTS) in women aged 50-75 with the metabolic syndrome (a cluster of conditions that occur together, increasing the risk of heart disease, stroke and type 2 diabetes). MitoQ, a strong mitochondrial-targeted antioxidant molecule, has been shown to target mitochondrial dysfunction, oxidative stress, inflammation, and endothelial dysfunction, all aging pathways that are also found to be dysregulated in conditions that cause LUTS such as the overactive bladder syndrome. Women aged 50-75 who have the metabolic syndrome per the new International Diabetes Federation (IDF) definition and have had urinary urgency for at least 3 months will be invited to participate in the study. They will be screened by phone for major study inclusion/exclusion criteria and then invited for an in-person screening visit where blood will be drawn and measurements taken to confirm eligibility. Once eligible, participants will be randomly assigned to MitoQ or placebo (2MitoQ:1placebo) and asked to take 2 capsules daily (40mg MitoQ total) 30 minutes before breakfast for 4 months. Participants will come back for study visits at 8 and 16 weeks, and will receive two study data collection phone calls at 4 and 12 weeks, where they will answer questions about their bladder. There will be many other shorter phone calls throughout the study to check for adherence and adverse events. In addition to questionnaires assessing bladder function, participants will undergo tests of frailty, physical function, cognitive function and asked many questions about their health and medication. We will also draw blood for safety assessment and to measure aging molecules in the blood at each visit and see whether they change with treatment. Urine will also be collected at each study visit and participants will be asked to collect urine at home (first morning and 24-hour urine) and bring it to each of their study visits, which will be used for measuring aging molecules and testing how they change with the study drug. Participants will also fill out three-day voiding diaries to provide information about their voiding and LUTS.
Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
PURPOSE:To provide the subject preparation containing a slightly digestable saccharide and/or a sugar alcohol, dissolving an averse drinking feeling caused by the different feeling of the barium salt preparation on oral administration and also dissolving the difficulty of the exertion of the barium salt preparation after the oral adminisration. CONSTITUTION:A slightly digestable saccharide (e.g. an oligosaccharide prepared by combining lactulose, raffinose or lactose with fructose) and/or a sugar alcohol (e.g. mannitol or lactitol) are added in amounts of 0.01-0.7pt.wt. based on 1pt.wt. of a water-soluble barium salt to an X ray contrast preparation containing a water-insoluble barium salt. Since hot digested and adsorbed is human digestive tracts, the slightly digestable saccharide and the sugar alcohol hold water and stay in the digestive tracts, thereby acting as a laxative accelerating the excretion of the barium salt preparation, and exhibit sweetness when co-existing with the barium salt, thereby permitting to easy administration of the barium salt preparation.
The invention belongs to the technical field of vaccines, and particularly discloses a multi-epitope oral vaccine targeting M cells, which comprises a carrier, targeting peptide Co1 of the M cells, and CD4 specifically aiming at restriction sites of DLA of dogs  +  T cell epitope peptide, CD4 specific for canine DLA restriction site  +  The amino acid sequences of the T cell epitope peptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The invention also discloses application of the M cell targeted multi-epitope oral vaccine in a hydatid vaccine. The M cell targeted multi-epitope oral vaccine provided by the invention effectively reduces hydatid cyst in mice, is convenient to produce, and is not limited by immune operators.
The invention discloses an adenovirus vector for specifically inhibiting proliferation and migration of smooth muscle cells and application of the adenovirus vector. Target genes and miRNA regulatory sequences are inserted at multiple clone sites of the adenovirus vector. After atherosclerosis disease interventional therapy, a main principle of restenosis lies in that the smooth muscle cells migrate to an intima and perform pathological proliferation. The adenovirus vector disclosed by the invention is applied, so that the movement of the proliferation, the migration and the like of the smooth muscle cells can be well restrained, and restenosis can be avoided. The adenovirus vector is adjusted and controlled based on miRNA, so that the purpose of specifically inhibiting proliferation and the migration of vascular smooth muscle cells can be realized, and influence on vascular endothelial cells is little. Therefore, the repair of endothelium is not influenced, so that the risk of thrombosis is reduced, and the use of antiplatelets and bleeding can be reduced; the effect of interventional treatment of the atherosclerosis diseases can be improved.
The goal of the Cellular and Tissue Based Therapy Registry (CTPR) for Wounds is to provide comparative effectiveness data for patients with chronic wounds and ulcers and to understand whether clinical practice guidelines are followed in the use of these products. These products are referred to by a variety of names of which are inaccurate reflections of their structure or purpose (e.g. Cellular and Engineered Tissue Alternatives, "bioengineered tissues," "biological dressings"). The preferred term is cellular and/or tissue based products (CTPs). CTPs are utilized for their biological influence on the healing process by stimulating or supporting healing. They may or may not be incorporated into regenerating tissue. Both tissue derived and biosynthetic products may be made with or without dead cells and biomaterials made of living cells may be comprised of autologous cells (cultured and not cultured), xenogenic, or allogenic cells (minimally manipulated, cultured, immortal).The diversity of products and the rate at which they are becoming available for clinical use make it impossible to perform randomized controlled trials to compare their effectiveness against one another. Effectiveness in real world patients is the best current option to understand the role of CTPs in wound healing.

Hospital based outpatient wound centers participating in the US Wound Registry agree to provide data as part of quality initiatives and to meet their Stage 2 Meaningful use criteria. The CTPR is a subset of the USWR data. All patient data from all participating outpatient clinics are transmitted to the USWR where it is available for benchmarking, PQRS and other initiatives. Data used for effectiveness research is HIPAA de-identified. These data are derived from structured language entries directly transmitted from electronic health records which also link to billing and charge documents once practitioners sign and lock charts, confirming the veracity of data entries.
Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
* Take topiramate tablets exactly as prescribed.
  * Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.
  * Topiramate tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.
  * Do not store any medicine and food mixture for later use.
  * Topiramate tablets can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent kidney stones while taking topiramate.
  * If you take too much topiramate, call your healthcare provider or poison control center right away or go to the nearest emergency room.
  * If you miss a single dose of topiramate, take it as soon as you can. However, if you are within 6 hours of taking your next scheduled dose, wait until then to take your usual dose of topiramate, and skip the missed dose. Do not double your dose. If you have missed more than one dose, you should call your healthcare professional for advice.
  * Do not stop taking topiramate without talking to your healthcare provider. Stopping topiramate suddenly may cause serious problems. If you have epilepsy and you stop taking topiramate suddenly, you may have seizures that do not stop. Your healthcare provider will tell you how to stop taking topiramate slowly.
  * Your healthcare provider may do blood tests while you take topiramate.
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
The invention discloses recombinant human-like collagen containing hydroxyproline and hydroxylysine and a production method thereof. The nucleotide sequence of the recombinant human-like collagen containing hydroxyproline and hydroxylysine is shown as SEQ ID NO. 1; the amino acid sequence of the recombinant human-like collagen containing hydroxyproline and hydroxylysine is shown as SEQ ID NO. 5. The recombinant human-like collagen is obtained by using Kluyveromyces as a chassis cell, respectively coexpression of four different vectors, namely pKLAC1-hlCOL, pKLC-P4HA, pKLC-PDI and pKLC-LH, and a series of fermentation and purification methods. The hydroxylation rate of the recombinant human-like collagen proline and lysine is similar to that of natural human-like collagen I, and reaches 30.7% and 43.1% respectively. Compared with non-hydroxylated recombinant human-like collagen, the collagen has better functions of promoting cell adhesion and promoting wound healing.
Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
The agricultural fumigant pesticide aluminum phosphide (AlP) is cardiotoxic. Water causes AlP to emit phosphine gas, a cardiac toxin that affects heart function and causes cardiogenic shock. AlP poisoning's high fatality rate is due to cardiotoxicity. This study examines how resveratrol reduces oxidative stress, mitochondrial activity, and apoptosis in human cardiac myocyte (HCM) cells. After determining the optimal doses of resveratrol using the MTT test, HCM cells were subjected to a 24-h treatment of resveratrol following exposure to AlP (2.36 μM). The levels of reactive oxygen species (ROS), superoxide dismutase (SOD) activity, mitochondrial swelling, mitochondrial cytochrome c release, and mitochondrial membrane potential (MMP) in HCM cells were investigated. Also, the expression of Bax and Bcl-2, caspace-3 activity, and apoptosis were assessed. The present investigation revealed that AlP substantially increased the level of ROS and decreased SOD activation, which were significantly modulated by resveratrol in a dose-dependent manner. Moreover, AlP induced an elevation of mitochondrial swelling, cytochrome c release, and MMP collapse. Co-administration of resveratrol significantly reduced above mitochondrial markers. AlP also significantly upregulated BAX and downregulated Bcl-2 expression, elevated caspace-3 activity, and apoptosis. Resveratrol co-administration was able to meaningfully modulate the mentioned parameters and finally reduce apoptosis. In conclusion, resveratrol, via its pleotropic properties, significantly demonstrated cytoprotective effects on HCM cytotoxicity induced by AlP.
PURPOSE: Temporal bone paraganglioma (TBP) are the most common tumors of the middle ear. They pose a challenge in otologic surgery due to their extensive vascularity and intricate location within the middle ear. This meta-analysis aimed to compare the safety and efficacy of two surgical approaches, microscopic middle ear surgery (MMES) and endoscopic middle ear surgery (EMES), in the resection of TBP.
METHODS: Eligible studies published after 1988 were identified through systematic searches of "PubMed", "Scopus" and "Google Scholar". Retrospective studies and randomized/non-randomized control trials reporting on surgical approaches for TBP with a minimum of five adult patients were included.
RESULTS: A total of 595 records were initially identified. After removing 229 duplicates, 349 articles were excluded based upon article subject, title and abstract. Following the review of full texts, 13 articles were assessed for eligibility. The pooled analysis included a total of 529 ears, with a complication rate of 7.8% for EMES and 14.2% for MMES. Subgroup differences indicated no significant variation between the two methods (p = 0.2945).
CONCLUSION: Both EMES and MMES demonstrated favorable surgical outcomes with low complication rates for TBP resection. These findings suggest that EMES is a safe and effective method for TBP resection and one that is comparable to MMES. Since the risk of bleeding is significant in these tumors, a third-hand technique, endoscopic bipolar cautery or laser-assisted hemostasis should be considered. Conversion to MMES is another option when visibility is critically affected by bleeding.
Morgan, RM, Wheeler, TD, Poolman, MA, Haugen, ENJ, LeMire, SD, and Fitzgerald, JS. Effects of photobiomodulation on pain and return to play of injured athletes: A systematic review and meta-analysis. J Strength Cond Res 38(6): e310-e319, 2024-The aims of this systematic review and meta-analysis were to evaluate the effect of photobiomodulation (PBM) on musculoskeletal pain in injured athletes and to determine if the effects of PBM allowed injured athletes to return to play faster. Electronic databases (MEDLINE Complete, CINAHL, and SPORTDiscus, PubMed, Web of Science, and Embase) were systematically searched (up to and including November 7, 2023) for peer-reviewed randomized controlled trials (RCTs) meeting criteria. Six RCTs, representing 205 competitive and recreational athletes with a mean age of 24 years, were included in the analysis. There were 6 intervention groups using standard physical therapy (n = 1), placebo PBM (n = 4), and aloe gel (n = 1) lasting between 10 minutes and 8 weeks in duration. The level of significance set for the study was p < 0.05. Overall, the use of PBM indicated a positive effect on pain reduction for PBM vs. control groups, standardized mean differences = 1.03, SE = 0.22, 95% confidence intervals = [0.43-1.63], p = 0.0089, but the 2 RCTs found evaluating the effect of PBM on time to return to play after injury in athletes do not support a benefit. Allied healthcare professionals may use PBM to reduce pain, thus allowing an athlete to return to their normal biomechanical movement faster; however, limited evidence suggests that PBM does not reduce time to return to play after an injury.
BACKGROUND: Intestinal adenocarcinoma accounts for less than 0.1-4% of all malignancies in the region. It is common among woodworkers and leather workers. Sinonasal adenocarcinoma usually arises from the ethmoid sinus (40%) or nasal cavity (25%). Extension to nearby structures is common, but intracranial spread is very rare. These tumors are usually treated with surgery, with a reported 5-year survival rate of 59% to 80%.
CASE PRESENTATION: This is a 60-year-old Black African male patient who presented with globalized headache, nasal obstruction with snoring during sleep, anosmia, change in mentation, sometimes agitation and left-side visual loss of one-year duration with worsening his above symptoms over the last one month. He couldn't smell soap bilaterally; in his left eye he could see only hand movement at nearly 30 cm. On brain magnetic resonance imaging, there was a T1 hypo- and T2 hyper-intense anterior cranial fossa mass arising from the left ethmoid sinuses and sphenoid sinuses and compressing the left optic structures, and brain computed tomography demonstrated heterogeneous hypo- to isodense mass. Complete tumor excision achieved and discharged with significant improvement and linked to oncology unit for radiotherapy.
CONCLUSION: The management of these patients is multidisciplinary, involving neurosurgeons, otolaryngologists, oncologists, and maxillofacial surgeons. Surgical resection is the main treatment strategy, followed by radiotherapy, particularly intensity-modulated therapy. Chemotherapy is used in highly advanced, metastatic, and unresectable tumors.
METHODS: 30 male patients with primary inguinal hernias undergoing primary inguinal herniorrhaphy were prospectively recruited for ilioinguinal nerve resection and evaluation. Three samples of the resected ilioinguinal nerve (proximal, canal, and distal) were evaluated using Masson's trichrome stain to measure fascicle and total nerve cross-sectional area and detect changes in collagen.
RESULTS: The fascicle cross-sectional area in the canal segment was significantly decreased compared to the proximal control with a large effect size observed (p = 0.016, η2  = 0.16). There was no significant difference in the nerve cross-sectional area between locations, but there was a moderate to large effect size observed between locations (p = 0.165, η2  = 0.105). There was no significant difference in collagen content nor effect size observed between locations (p = 0.99, η2  = 1.503 × 10-4). Interpretation. The decrease in the fascicle cross-sectional area within the inguinal canal further suggests that there is chronic pressure applied by hernia tissue consistent with axon degeneration. Collagen content is uniformly distributed along the length of the nerve. Further studies with larger samples are needed to confirm the observed effect of nerve location on the total nerve cross-sectional area and axon loss.
PURPOSE: To obtain a sustained release pharmaceutical composition comprising a core element containing at least one highly soluble active ingredient and a core coating which is partially soluble at a highly acidic pH and provides a constant, relatively faster rate of release at a more alkaline pH such as that of the intestine over a long time, and little in the fluctuation of the blood concentration of the active ingredient and little in the change of the blood concentration for each administration. CONSTITUTION: This sustained release pharmaceutical composition comprises a core element comprising a highly soluble active ingredient (especially morphine), a core seed and a binder, and a core coating which is partially soluble at a highly acidic pH, provides a slow release of the active ingredient, and provides a constant, relatively faster rate of the release at a more alkaline pH such as that of the intestine to deliver to the blood levels of active ingredient within the therapeutic range and to maintain such levels over an extended period of time.  The core coating preferably comprises 1-85wt.%, especially 45-65wt.%, of a matrix polymer (e.g. ethyl cellulose) substantially insoluble without relating to pH, 1-60wt.%, especially 5-15wt.%, of a pH-dependent enteric polymer (e.g. methacrylic acid-ethyl acrylate copolymer), and 1-60wt.%, especially 20-35wt.%, of a component at least soluble at an acidic pH (e.g. polyvinyl pyrrolidone).
The primary purpose of this study is to demonstrate the safety and efficacy of the amikacin fosfomycin inhalation system (AFIS). AFIS consists of amikacin solution and fosfomycin solution, delivered by aerosol to the lungs via the PARI Investigational eFlow Inline System (eFlow Inline System). All patients will receive a standardized course of intravenous (IV) antibiotics for a minimum of 7 days. Patients will be randomized to receive 10 days of treatment with either AFIS or placebo, in addition to the IV therapy. The primary efficacy endpoint is defined as the change from baseline in the Clinical Pulmonary Infection Score (CPIS) during the randomized course of study drug. The study was designed to enroll up to 150 patients with the desire to enroll at least 140 patients with gram negative pneumonia. The study was terminated at 143 when that goal was achieved